NYSE:SNN - Smith & Nephew Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $47.17
  • Forecasted Upside: 23.15 %
  • Number of Analysts: 13
  • Breakdown:
  • 2 Sell Ratings
  • 5 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$38.30
▼ -1 (-2.54%)
1 month | 3 months | 12 months
Get New Smith & Nephew Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$47.17
▲ +23.15% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Smith & Nephew in the last 3 months. The average price target is $47.17, with a high forecast of $53.00 and a low forecast of $42.00. The average price target represents a 23.15% upside from the last price of $38.30.
Hold
The current consensus among 13 polled investment analysts is to hold stock in Smith & Nephew. This rating has held steady since April 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
9/10/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/9/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/8/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 2 sell ratings
6/6/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 2 sell ratings
9/4/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 2 sell ratings
12/3/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 2 sell ratings
2/1/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 2 sell ratings
3/3/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 2 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2021Berenberg BankReiterated RatingBuyLow
i
2/22/2021JPMorgan Chase & Co.Reiterated RatingNeutralMedium
i
2/22/2021Credit Suisse GroupReiterated RatingNeutralMedium
i
2/22/2021CommerzbankDowngradeBuy ➝ HoldLow
i
2/19/2021Canaccord GenuityLower Price TargetBuy$55.00 ➝ $53.00Medium
i
1/22/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
1/21/2021BarclaysReiterated RatingOverweightLow
i
1/20/2021Berenberg BankReiterated RatingBuyMedium
i
12/18/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
12/18/2020Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$46.50Medium
i
12/9/2020Morgan StanleyReiterated RatingOverweightLow
i
12/1/2020BarclaysInitiated CoverageOverweightLow
i
10/30/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
10/30/2020Canaccord GenuityLower Price TargetBuy$50.00 ➝ $48.00Low
i
7/31/2020Berenberg BankReiterated RatingBuyLow
i
7/30/2020JPMorgan Chase & Co.Reiterated RatingNeutralMedium
i
7/30/2020Morgan StanleyReiterated RatingOverweightHigh
i
7/29/2020Bank of AmericaUpgradeNeutral ➝ BuyLow
i
7/10/2020Berenberg BankReiterated RatingBuyLow
i
6/5/2020BNP ParibasDowngradeNeutral ➝ UnderperformLow
i
6/5/2020Exane BNP ParibasDowngradeNeutral ➝ UnderperformLow
i
6/4/2020Morgan StanleyUpgradeEqual Weight ➝ OverweightLow
i
5/11/2020Berenberg BankReiterated RatingBuyLow
i
5/7/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
5/7/2020CfraLower Price TargetHold$52.00 ➝ $42.00Low
i
4/14/2020CitigroupDowngradeBuy ➝ NeutralMedium
i
3/31/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
2/21/2020CfraBoost Price TargetHold$46.00 ➝ $52.00Medium
i
11/21/2019CitigroupInitiated CoverageBuyLow
i
11/12/2019Sanford C. BernsteinInitiated CoverageOutperformLow
i
7/23/2019Berenberg BankUpgradeHold ➝ BuyLow
i
5/3/2019Canaccord GenuityReiterated RatingBuy$6.00High
i
4/25/2019Canaccord GenuityBoost Price TargetBuy ➝ Buy$43.00 ➝ $45.00Low
i
4/8/2019Canaccord GenuityReiterated RatingAverage ➝ Buy$10.00Low
i
2/8/2019BNP ParibasDowngradeOutperform ➝ NeutralLow
i
1/1/2019JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralMedium
i
12/10/2018Morgan StanleyUpgradeEqual Weight ➝ OverweightMedium
i
12/7/2018Deutsche Bank AktiengesellschaftUpgradeSell ➝ HoldMedium
i
11/1/2018Canaccord GenuityReiterated RatingBuy ➝ BuyLow
i
10/16/2018HSBCDowngradeBuy ➝ HoldMedium
i
8/8/2018UBS GroupDowngradeBuy ➝ NeutralLow
i
8/6/2018Canaccord GenuityReiterated RatingBuy$42.00Low
i
5/3/2018Deutsche Bank AktiengesellschaftDowngradeHold ➝ SellLow
i
4/18/2018UBS GroupUpgradeNeutral ➝ BuyLow
i
3/26/2018HSBCUpgradeHold ➝ BuyHigh
i
2/8/2018Canaccord GenuityReiterated RatingBuyMedium
i
1/25/2018JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightLow
i
1/5/2018Canaccord GenuityReiterated RatingBuy$45.00Low
i
12/11/2017Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
i
10/11/2017Canaccord GenuityInitiated CoverageBuy$42.00N/A
i
2/27/2017The Goldman Sachs GroupDowngradeBuy ➝ NeutralN/A
i
2/15/2017Berenberg BankReiterated RatingHoldN/A
i
12/8/2016Morgan StanleyUpgradeEqual Weight ➝ OverweightN/A
i
11/8/2016Bank of AmericaReiterated RatingBuyN/A
i
11/7/2016Deutsche Bank AktiengesellschaftReiterated RatingHoldN/A
i
10/26/2016Deutsche Bank AktiengesellschaftReiterated RatingHoldN/A
i
10/6/2016Berenberg BankDowngradeBuy ➝ HoldN/A
i
8/10/2016Beaufort SecuritiesReiterated RatingHoldN/A
i
8/10/2016BarclaysDowngradeOverweight ➝ Equal WeightN/A
i
5/9/2016Jefferies Financial GroupUpgradeHold ➝ BuyN/A
i
4/11/2016Morgan StanleyReiterated RatingEqual WeightN/A
i
3/17/2016Nomura SecuritiesInitiated CoverageNeutralN/A
i
(Data available from 3/4/2016 forward)
Smith & Nephew logo
Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers knee implant products for specialized knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Read More

Today's Range

Now: $38.30
$37.96
$38.59

50 Day Range

MA: $42.73
$38.85
$45.88

52 Week Range

Now: $38.30
$26.07
$46.15

Volume

332,042 shs

Average Volume

393,672 shs

Market Capitalization

$16.80 billion

P/E Ratio

18.77

Dividend Yield

1.42%

Beta

0.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Smith & Nephew?

The following Wall Street sell-side analysts have issued stock ratings on Smith & Nephew in the last twelve months: Bank of America Co., Barclays PLC, Berenberg Bank, BNP Paribas, Canaccord Genuity, Cfra, Citigroup Inc., Commerzbank AG, Credit Suisse Group AG, Exane BNP Paribas, JPMorgan Chase & Co., Morgan Stanley, Sanford C. Bernstein, and Zacks Investment Research.
View the latest analyst ratings for SNN.

What is the current price target for Smith & Nephew?

3 Wall Street analysts have set twelve-month price targets for Smith & Nephew in the last year. Their average twelve-month price target is $47.17, suggesting a possible upside of 20.0%. Canaccord Genuity has the highest price target set, predicting SNN will reach $53.00 in the next twelve months. Cfra has the lowest price target set, forecasting a price of $42.00 for Smith & Nephew in the next year.
View the latest price targets for SNN.

What is the current consensus analyst rating for Smith & Nephew?

Smith & Nephew currently has 2 sell ratings, 5 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SNN, but not buy more shares or sell existing shares.
View the latest ratings for SNN.

What other companies compete with Smith & Nephew?

How do I contact Smith & Nephew's investor relations team?

Smith & Nephew's physical mailing address is BUILDING 5 CROXLEY PARK HATTERS LANE, WATFORD X0, WD18 8YE. The medical equipment provider's listed phone number is 44-19-2347-7100 and its investor relations email address is [email protected] The official website for Smith & Nephew is www.smith-nephew.com.